PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Published:2015-01 Issue:9965 Volume:385 Page:331-340
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Raal Frederick J,Stein Evan A,Dufour Robert,Turner Traci,Civeira Fernando,Burgess Lesley,Langslet Gisle,Scott Russell,Olsson Anders G,Sullivan David,Hovingh G Kees,Cariou Bertrand,Gouni-Berthold Ioanna,Somaratne Ransi,Bridges Ian,Scott Rob,Wasserman Scott M,Gaudet Daniel

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation;Watts;Int J Cardiol,2014

2. Familial hypercholesterolemia;Goldstein,2001

3. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society;Nordestgaard;Eur Heart J,2013

4. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolaemia database;Leigh;Ann Hum Genet,2008

5. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia;Hobbs;Hum Mutat,1992

Cited by 642 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention;Lipids in Health and Disease;2024-09-10

2. Real‐world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-09-06

3. Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab;Pharmacological Research;2024-09

4. Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives;Current Atherosclerosis Reports;2024-07-15

5. Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk;Medicina;2024-07-12